MTNB · XBRL financial data

Matinas BioPharma Holdings financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MTNB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	158	33	3,188	1,096	—	—
Research and development	14,359	14,583	16,678	14,489	11,433	85
General and administrative	10,006	10,185	11,100	10,373	8,729	6,875
Operating income (loss)	(24,207)	(24,735)	(24,590)	(23,766)	(24,593)	(6,960)
Other income (expense)	—	124	102	340	262	(261)
Income tax expense (benefit)	—	—	—	—	(80)	—
Net income (loss)	(22,447)	(23,283)	(20,997)	(22,942)	(24,251)	(10,345)
Earnings per share, basic USD per share	—	(0.11)	(0.10)	(0.11)	(4.98)	(2.00)
Earnings per share, diluted USD per share	—	—	(0.10)	(0.11)	(4.98)	(2.00)
Weighted average shares, basic thousands of shares	—	210,178	216,811	217,265	4,866	5,474
Weighted average shares, diluted thousands of shares	—	—	216,811	217,265	4,866	5,474

† Share count changed about 1/43 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (MTNB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	12,432	21,030	6,830	4,787	7,284	3,999
Marketable securities	46,247	28,592	21,933	8,969	—	—
Prepaid and other current assets	2,740	1,321	5,719	1,737	691	26
Total current assets	61,555	50,993	34,532	15,543	8,025	4,075
Property and equipment, net	1,524	1,538	2,091	1,923	468	138
Right-of-use asset	3,277	4,219	3,613	3,064	1,680	531
Goodwill	1,336	1,336	1,336	1,336	—	—
Total assets	70,967	61,326	44,819	25,104	12,641	7,208
Accounts payable	350	938	618	514	95	315
Accrued liabilities	2,795	2,851	3,099	1,447	1,801	452
Total current liabilities	3,568	4,349	4,286	2,622	2,666	1,463
Lease liability, non-current	3,304	4,140	3,533	2,877	2,116	653
Total liabilities	7,237	8,833	8,182	5,858	5,051	2,378
Accumulated deficit	(107,507)	(131,634)	(152,631)	(175,573)	(199,824)	(210,787)
Total stockholders' equity	63,731	52,493	36,637	19,246	7,590	4,830
Total liabilities and equity	70,967	61,326	44,819	25,104	12,641	7,208
Common shares outstanding (cover page) thousands of shares	204,276	216,865	217,265	217,483	5,087	6,406

† Share count changed about 1/43 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (MTNB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(22,447)	(23,283)	(20,997)	(22,942)	(24,251)	(10,345)
Stock-based compensation	4,565	4,292	5,228	4,948	3,195	1,023
Depreciation and amortization	231	244	337	385	365	32
Net cash from operating activities	(17,368)	(15,223)	(19,156)	(15,278)	(15,885)	(7,011)
Purchases of property and equipment	6	260	892	218	—	—
Net cash from investing activities	(40,667)	16,770	4,877	13,242	9,208	335
Proceeds from issuing common stock	—	—	—	—	9,179	—
Net cash from financing activities	48,047	6,965	79	(7)	9,174	3,391
Net change in cash	(9,988)	8,511	(14,200)	(2,043)	2,497	(3,285)

† Share count changed about 1/43 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Matinas BioPharma Holdings	761	not reported	(1,836)*	14.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Soligenix	9,811	not reported	(1,707)*	21.8M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Synlogic	13,183	0	(922)*	12.2M	14.3 quarters	Q2 FY26 10-QJun 30, 2026
Target Group	14	1,381	(223)*	617.0M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Creative Medical Technology Holdings	8,714	0	(1,472)*	6.6M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Aspira Women's Health	477	17	(2,010)*	46.6M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
China Pharma Holdings	305	948	(33)*	43.0M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Viskase Holdings	7,747	95,279	454*	14.3M	—	Q3 FY26 10-QSep 30, 2026
Healthy Extracts	190	2,067	306*	14.7M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.